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Abstract
Health Issues: Dementia, including Alzheimer's disease (AD) increases exponentially with age
from the age of 65. The number of people with dementia will increase significantly over the next
three decades as the population ages. While prevalence and incidence rates do not differ markedly
in women, compared to men, women live longer on average, so the number of women with
dementia is greater than for men. Also, women are more frequently caregivers for people with
dementia. Thus, dementia is an important health problem for women.
Key Findings: The Canadian Study of Health and Aging showed an increase in prevalence of
dementia with age for both sexes, approximately doubling every five years of age. Rates of AD were
higher in women whereas rates of vascular dementia were higher in men. The risk of AD increased
with increasing age, lower education, and apolipoprotein E ε4. Regular physical activity was clearly
protective in women; this was less clear for men. Use of non-steroidal anti-inflammatory drugs,
wine consumption, and past exposure to vaccines decreased the risk of AD. Estrogen replacement
therapy did not reduce the risk of AD. About three quarters of caregivers for dementia patients
were women.
Data Gaps and Recommendations: The protective effect of regular physical activity for AD
provides an additional reason to promote regular physical activity at all ages. Ongoing surveillance
of the incidence, prevalence and risks for dementia is needed to monitor the impact of treatments
as well as the aging of the population on the burden of dementia.
Background
Dementia involves "a chronic deterioration of intellectual
function and other cognitive skills severe enough to inter-
fere with the ability to perform activities of daily liv-
ing."[1] Dementia mainly affects seniors and also greatly
affects their families and caregivers. It includes Alzhe-
imer's disease (AD), the most common form of dementia,
vascular dementia, and other, rarer, conditions. AD has
been defined as "a progressive, inexorable loss of cogni-
tive function associated with an excessive number of
senile plaques in the cerebral cortex and subcortical gray
matter, which also contains β-amyloid and neurofibrillary
tangles consisting of tau protein."[1]
Two factors combine to make dementia an important
issue for women: first, the Canadian population is aging,
and the proportion of older people will increase rapidly
over the next few decades as the baby boomers become
seniors. The most rapid increase in the population is in
the "oldest old," aged 85 and over, and this is the age
group with the highest risk of dementia. Second, the aver-
age life expectancy is longer for women than men (81.1
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years for women and 75.1 years for men),[2] which means
that in older age groups the proportion of women
increases. Thus more women than men develop and live
with AD and other dementias.
With the aging of the Canadian population, it becomes
increasingly important to understand the effects of
dementia and AD on individuals, families, friends, car-
egivers, community health services and long-term care
facilities. This review offers a brief summary of the magni-
tude of dementia in Canada, research on risk factors and
preventive factors, caregiving issues, and health policy
implications.
Methods
Data Source
The Canadian Study of Health and Aging (CSHA) is a lon-
gitudinal, multi-centre, population-based study that pro-
vides a great deal of detailed data on dementia in Canada.
As the largest study of its kind, it is the only national, pop-
ulation-based study of dementia in the world. It was
designed to focus on the prevalence, incidence, risk factors
and caregiving patterns related to dementia in elderly
Canadians. The study methods have been more thor-
oughly described elsewhere. [3-6]
During the first phase of the study (CSHA1), conducted in
1991–1992, representative samples of people aged 65 or
older were randomly chosen from 36 urban and sur-
rounding rural areas in the 10 Canadian provinces. The
total sample was 10,263 people, including 9,008 commu-
nity residents and 1,255 residents of institutions. There
were 4,008 men and 6,255 women, providing a large sam-
ple that could be weighted to the population for popula-
tion estimates of prevalence and incidence.
Community subjects were interviewed at home and
screened for cognitive impairment using standardized,
validated instruments. Those who were deemed to be
impaired, a random sample of those who were not, and
all participants in institutions were offered an extensive
clinical evaluation involving a nurse, a physician, a psy-
chometrist and a neuropsychologist. Consensus diag-
noses classified subjects into one of the following
categories: no cognitive impairment, cognitive impair-
ment no dementia (CIND), AD (probable or possible),
vascular dementia, other specific dementia, and unclassi-
fiable dementia.
Subjects found to have AD for less than three years or to
have vascular dementia became part of case-control stud-
ies of risk factors. [5-7] Control subjects were selected
from those who screened negative and who were clinically
diagnosed as cognitively normal. In addition, those
deemed cognitively normal completed a questionnaire for
prospective studies of risk factors. Risk factor data were
obtained from proxies for both cases and controls for the
initial retrospective analyses.
The caregiver study involved interviews with primary car-
egivers of subjects with dementia and caregivers of a sam-
ple group of subjects who were cognitively normal.
In the 1996–1997 study (CSHA2), the participants were
followed up to measure changes in health status and func-
tioning an average of five years after CSHA-1. Subjects
went through the same diagnostic process as in CSHA-1.
For participants who died before CSHA-2, the date and
cause of death were obtained, and a relative or other
informant was interviewed.
Data Quality
The quality of the CSHA data is high. The initial commu-
nity screening test was chosen in part because of its relia-
bility and validity, and a high cut-point was used to
increase sensitivity. Diagnosis of dementia, including sub-
types, was made using carefully standardized, in-depth
clinical examinations following a multi-stage protocol,
and the latest criteria were applied. Response rates were
high. All questionnaires were thoroughly checked and
coded; data were double-entered until an error rate of less
than 1 per 1,000 variables was reached.
Results
Prevalence
From the CSHA-1 it was estimated that over a quarter of a
million (252,600) seniors in Canada suffered from
dementia in 1991, representing 8% of the population
aged 65 or older (Figure 1).[3] More women than men
had dementia (171,400 versus 81,200), although there
was less difference in the prevalence rate (86 versus 69 per
1,000 population, respectively). This included 118,300
women and 42,700 men with AD, with rates of 58 and 38
per 1,000 population respectively.
Half (51%) of those with dementia were living in institu-
tions. Of those with dementia living in the community,
almost two thirds (63%) were women, whereas in institu-
tions almost three quarters (72%) of those with dementia
were women.
AD was the most common form of dementia in women;
it was diagnosed in 69% of women with dementia versus
53% of men with dementia. In contrast, only 14% of
women with dementia had vascular dementia, compared
with 30% of men.
The rates of dementia increased markedly with age for
both sexes. Among women, 28 per 1,000 of those aged 65
to 74 had dementia; this increased to 116 per 1,000 forBMC Women's Health 2004, 4:S20 http://www.biomedcentral.com/1472-6874/4/S1/S20
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women aged 75 to 84, and 371 per 1,000 for those aged
85 and over. The corresponding rates for men were 19,
104 and 287 per 1,000. Thus there was relatively little dif-
ference in the rates among men and women except in the
85+ age group. In contrast, the proportions of women in
the two older age groups were substantially higher: 63%
of those aged 75 to 84 with dementia were women, and
75% of those aged over 85.
Projections of prevalent cases of dementia were calculated
on the basis of the changing age composition of the Cana-
dian population up to 2031 and are presented in Figure
2.[3] They are based entirely on the projected increases in
the population aged 65 and over and assume no changes
in prevalence due to changes in risk factors, treatment or
survival.
Incidence
Based on the 1991 population, the CSHA-2 follow-up
study provided estimates of 60,150 incident (new) cases
of dementia in Canada's population aged 65 and over
each year.[6] The majority (60%) of new cases were
women (36,320), and the overall age-standardized rate
was 21.8 women per 1,000 non-demented population.
The incidence rate among men was very similar (19.1 per
1,000 non-demented population). More than one fifth
(22%) of new cases occurred in institutions. The approxi-
mate doubling of incidence rates with every five years of
age has been seen in many studies.[8]
The CSHA prevalence and incidence rates of dementia
seem to generally fall within the range of other commu-
nity-based European and U.S. studies,[6,9-13] although
towards the upper end of the distribution.[14] This may
reflect the fact that the CSHA included both institutional
and community samples as well as milder cases of
dementia. The larger number of women with dementia,
despite the comparatively small difference in prevalence
and incidence rates, reflects the larger number of women
Prevalence of dementia in Canada, 1991, by type of dementia, sex and age group – numbers and rates per 1,000 population Figure 1
Prevalence of dementia in Canada, 1991, by type of dementia, sex and age group – numbers and rates per 
1,000 population Source: Canadian Study of Health and Aging Working Group. Study methods and prevalence of 
dementia.[3]BMC Women's Health 2004, 4:S20 http://www.biomedcentral.com/1472-6874/4/S1/S20
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in the population due to their longer life expectancy as
well as their longer survival with dementia.
Mortality
Dementia is a major risk factor for mortality. A follow-up
investigation two years after the CSHA baseline study
revealed that the greatest mortality risk was among
women with dementia in institutions, whose risk of dying
was six times as great as cognitively normal women in the
community.[15] Five-year follow-up confirmed that eld-
erly people with dementia had clearly increased mortality
rates in all age-sex categories as compared with those who
were cognitively normal.[16] Mortality increased strongly
with age for people with all dementia subtypes.
Among women, those with vascular dementia experi-
enced the worst prognosis, the five-year mortality ranging
from 60% in the 65 to 74 age group to 83% in the over 85
group.[16] Among women with AD the prognosis was
only slightly better, with a corresponding mortality range
of 58% to 82%. Although the proportion of women dying
within five years of CSHA-1 diagnosis was lower than
among men in most of the dementia subgroups, the mor-
tality rate ratios (mortality relative to the general popula-
tion) were higher among women in most groups.
CSHA five-year follow-up data were also analyzed to esti-
mate duration of survival from the onset of dementia
symptoms, adjusting for length bias (failure to include
people with rapidly progressive illness who died before
being included in the study).[17] The unadjusted median
survival among subjects with probable AD, possible AD
and vascular dementia was 6.6 years, whereas the adjusted
estimate was only 3.3 years. The median survival was 3.1
years for subjects with probable AD, 3.5 for possible AD
and 3.3 for vascular dementia. Age at onset was the strong-
est predictor of survival: survival decreased as age at onset
of dementia increased. Women survived for slightly
longer with dementia than men (3.4 versus 3.2 years).
Risk Factors for AD
The CSHA published data on risk factors for AD from a
retrospective analysis of CSHA-1 data[5] and from a pro-
spective analysis of incident cases.[18] We will focus on
the longitudinal results, given the methodological advan-
tage of this type of study design.
Briefly, the CSHA-1 analysis showed that age, family his-
tory of dementia, and lower educational level were signif-
icantly associated with an increased risk of AD.[5] Head
injury slightly increased the risk, with borderline statisti-
cal significance. Study participants who had arthritis or
who used non-steroidal anti-inflammatory drugs
(NSAIDs) showed a significantly reduced risk of AD.
Analysis of CSHA-2 prospective incidence data revealed a
slightly different picture of risk factors for AD. Increasing
age, low educational level and apolipoprotein E-ε4 (apoE-
4) were significantly associated with increased risk of
AD.[18] Regular physical activity, use of NSAIDs, wine
consumption, past exposure to vaccines, and pre-existing
arthritis were significantly associated with decreased risk
of AD. [18-20] No statistically significant association was
found for family history of dementia, sex, estrogen ther-
apy, history of depression, head trauma, use of antiperspi-
rant or antacid (containing aluminum), smoking, high
blood pressure, heart disease or stroke (Figures 3 and 4).
Increasing age and the presence of the apoE-4 allele are
solidly established risk factors for AD.[14,21] Although a
positive family history of dementia is generally consid-
ered to be the only other definite risk factor, the CSHA-2
study did not find it to be significantly related to AD (con-
trary to the CSHA-1 prevalence study). However, these
results are consistent with findings from the EURODEM
pooled analysis of four European incidence studies.[22] It
has been suggested that increased risk in first-degree rela-
tives of AD patients may be related to relatively early onset
of AD.[23]
The association of higher educational level with a reduced
risk of AD is supported by several other prospective inci-
dence studies in Europe and the United States.[22,24-27]
Some of these studies found this association to exist for
women only[27]or to be stronger for women.[26]
Projected Prevalence of Dementia (× 1,000) Canada, 1991– 2031 Figure 2
Projected Prevalence of Dementia (× 1,000) Canada, 
1991–2031. Based on Table 11 in: Canadian Study of Health 
and Aging Working Group. Canadian Study of Health and 
Aging: study methods and prevalence of dementia. CMAJ 
1994;150:899–913.BMC Women's Health 2004, 4:S20 http://www.biomedcentral.com/1472-6874/4/S1/S20
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Notably, the CSHA-2 incidence study did not find sex to
be a significant risk factor for AD.[18] A prospective study
in East Boston also found that age-specific incidence of
AD did not differ significantly by sex.[28] Prospective
Association of family history of dementia, APOE ε4 status, coexisting or antecedent selected diseases, and prior use of medica- tion with risk of AD Figure 3
Association of family history of dementia, APOE ε4 status, coexisting or antecedent selected diseases, and 
prior use of medication with risk of AD, Canadian Study of Health and Aging, women, 1996.
APOE = apolipoprotein E;   
NSAIDs = Non-steroidal anti-inflammatory drugs.
OR = odds ratio;   
CI = confidence interval.  
* Adjusted for age and education. 
** Comparison group is E3/E3.  
† Statistically significant  BMC Women's Health 2004, 4:S20 http://www.biomedcentral.com/1472-6874/4/S1/S20
Page 6 of 9
(page number not for citation purposes)
studies in Europe have identified female sex as a risk factor
for incidence of AD, but only after age 85 or 90.[19,29]
Several protective factors for AD were identified in the
CSHA-2 that have implications for preventive strategies.
Arguably the most important was regular physical activity,
a modifiable lifestyle habit that reduced the risk of AD by
up to 50%.[20] Significant trends of increased protection
with higher levels of physical activity were observed for
AD and dementia of any type as well as for cognitive
impairment with no dementia. The associations between
physical activity and risk of CIND, dementia or AD were
strongest in women, with a reduction in risk of AD of
approximately 60% among women with high levels of
physical activity, as compared with no physical activity.
Although the literature is not entirely consistent, this find-
ing has been supported by other studies.[18]
Regular use of NSAIDs was significantly related to a 35%
reduction in the risk of AD in the CSHA-2 results.[18] This
protective effect was observed in several population-based
case-control studies, including the CSHA-1. [30-32] At
least two other longitudinal studies have supported the
CSHA-2 finding,[33,34] but others reported inconclusive
results.[35,36] Although it is encouraging that use of
NSAIDs may help to protect against AD, it also raises con-
cern about potential side effects, particularly gastrointesti-
nal bleeding.
Regular wine consumption was also significantly associ-
ated with reduced risk of AD (Odds Ratio [OR] 0.49) in
CSHA-2 analyses,[18] and the protective effect appeared
to be even stronger in women (OR 0.38). This protective
relation is consistent with findings from a longitudinal
study in France.[37] It has been suggested that specific
substances in wine (not alcohol) have a positive effect on
nerve cells.[38] Recently, however, a longitudinal study in
the Netherlands found a significant association between
light to moderate drinking and lower risk of dementia, but
with no evidence of any variation by type of alcoholic bev-
erage.[39] There are also the detrimental effects of alcohol
to be considered.
Another possible protective factor for AD identified in
CSHA-2 analyses was past exposure to vaccines against
diphtheria or tetanus, poliomyelitis, and influenza.[19]
After adjustment for age, sex and education, vaccines
against diphtheria or tetanus and against poliomyelitis
were significantly associated with lower risks of AD (60%
and 40% lower respectively). Influenza vaccine was also
related to a lower risk of AD, but the association did not
reach statistical significance. Further adjustments for other
Association of specific lifestyle variables with risk of AD Figure 4
Association of specific lifestyle variables with risk of AD, Canadian Study of Health and Aging, women, 1996BMC Women's Health 2004, 4:S20 http://www.biomedcentral.com/1472-6874/4/S1/S20
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lifestyle-related characteristics produced similar results.
These findings are consistent with the hypothesis that
changes in the immune system may be involved in aging
and AD, but this remains to be verified in further epidemi-
ologic and clinical studies.
Estrogen therapy in the past was thought to reduce the risk
of AD. The CSHA did not see a protective effect,[18] and
other studies have yielded inconsistent findings.[40,41] A
longitudinal study in the United States found that estro-
gen use was not protective against cognitive decline
related to aging, although the authors noted that their
study included few women who used estrogen for two
years or longer.[42] In contrast, a prospective study found
that women who formerly used hormone therapy had a
reduced risk of AD, as did current users whose treatment
exceeded 10 years.[43] More recently, a redundant publi-
cation of the Women's Health Initiative has shown an
increased risk of AD among women in the estrogen/pro-
gesterone arm of the study.[44]
Informal Care
As dementia progresses in individuals, it affects not only
them but also their caregivers. The CSHA-1 confirmed the
presence of an extensive informal network of Canadians
providing care to seniors with dementia.[4] Over 98% of
the estimated 123,900 seniors with dementia in the com-
munity had a caregiver. Of these caregivers, 94% were
informal caregivers, namely, unpaid family members or
friends. Of the dementia patients in the community, 94%
had two or more relatives or friends besides their primary
caregiver who assisted them.
Women's strong caregiving role was clearly demonstrated
in the CSHA data. Three quarters of the primary caregivers
of those with dementia in the community were women, as
were 71% of primary caregivers of dementia patients in
institutions.[4] In the community, almost one quarter
(24%) of these primary caregivers were wives, and 29%
were daughters. Daughters represented 45% of the infor-
mal caregivers of institutionalized dementia patients.
Other characteristics of the informal primary caregivers of
elderly dementia patients were notable. More than 70%
were married, whether the senior lived in the community
or an institution.[4] Friends and other family (i.e. neither
spouses nor children) made up over one fifth of these car-
egivers in both residential settings. Caregivers in the com-
munity were less likely to be employed (29%) than
caregivers of dementia patients in institutions (41%). The
average age of community caregivers was 62, but 32% of
them were aged 70 to 90;[45] 60% of the community car-
egivers lived with the dementia patient.
Caring for someone with dementia tends to negatively
affect the well-being of the caregiver. Informal caregivers
of seniors with dementia experienced more chronic health
problems and depressive symptoms than those caring for
a senior without dementia.[4] Caregivers of dementia
patients in institutions were less likely to feel burdened
and experienced less depression than the community car-
egivers, even though the severity of dementia was higher.
After five years, caregivers of dementia patients who
remained in the community reported significantly more
burden than did caregivers of patients who moved into or
remained in an institution.[46] A higher frequency of
disturbing behaviours, community residence of the
patient, and low informal support were associated with
greater caregiver burden, which in turn led to more
depression in the caregiver.[47] Furthermore, caregivers of
dementia patients with more disturbing behaviours and
greater functional disabilities received less help from fam-
ily and friends than did caregivers of dementia patients in
institutions.
Use of community care services in the CSHA-1 (in 1991)
seemed low, although data were not collected on the
availability of services.[4] Except for home physiotherapy,
use of community services was higher among those caring
for seniors with dementia than among those caring for
seniors without dementia. However, when patients were
matched for level of disability (measured by problems
with activities of daily living), except for moderate disabil-
ity, caregivers of dementia patients received fewer services
than those of non-dementia patients.
Possible factors affecting access to community care serv-
ices related to both care recipients and caregivers in the
CSHA analyses. Having greater functional disabilities, liv-
ing alone, living in a less urban environment and being
older were identified as predictors of use of community
care services by seniors with dementia.[48,49] Caregivers
who were children of dementia patients used more serv-
ices than those who were spouses.[4] In addition, caregiv-
ers who perceived their own health more poorly were
more likely to use community services to help in caring
for dementia patients.[48]
Institutionalization
In 1991, it was estimated from CSHA-1 data that 51% of
Canada's elderly population with dementia lived in insti-
tutions.[3] Five years later, CSHA-2 follow-up revealed
that 51% of the dementia patients in the community-
dwelling CSHA-1 caregiver study sample had been admit-
ted to an institution.[50] The median time to admission
was 41 months.
Similar to the use of community care services, the factors
affecting the likelihood of admission to an institutionBMC Women's Health 2004, 4:S20 http://www.biomedcentral.com/1472-6874/4/S1/S20
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involved characteristics of both dementia patients and
their caregivers.[50] The patient's type of dementia,
namely possible or probable AD, and the severity of disa-
bility in activities of daily living were significant predictors
of admission to an institution. The caregiver's age over 60,
not being a spouse or child of the patient, and severe car-
egiver burden were significantly associated with the care
recipient's placement in an institution. Caregiver burden
was strongly correlated with the patient's behavioural
problems and the caregiver's depressive mood. The car-
egiver's desire to have the dementia patient admitted to an
institution was related to the severity of the dementia,
being unable to leave the patient alone, living with the
patient, using two or more home care services, and level
of caregiver burden.
In addition, the risk of being admitted to an institution
was significantly higher among dementia patients living
in Quebec, the Prairies or British Columbia than for those
living in Ontario or the Atlantic provinces.[50]
Recent analyses of the CSHA data show that there was a
significant relation between service use and the functional
abilities (activities of daily living) of subjects, and that
their physical limitations predicted use of services whereas
cognitive problems did not.
Discussion
Limitations
The CSHA is internationally recognized as one of the best
studies of the epidemiology of dementia; in addition it
covered many other topics related to aging. It was well
designed and conducted. More frequent follow-ups
would have strengthened the study and reduced the
uncertainties in calculating incidence that arose because
of the larger number of people who died between phases
of the study. Collection of risk factor data for the case-con-
trol analyses was limited by the abilities of proxies to
respond for the study participants and provide the
amount of detail that was requested. The same questions
were asked of those who were cognitively normal, who
completed risk factor information for the prospective
analyses. This had the advantage of making the retrospec-
tive and prospective analyses comparable, but the disad-
vantage that there was not more detailed information for
the prospective analyses. The caregiving data, with hind-
sight, might have benefited from the collection of addi-
tional information – for example, about the availability of
services; however, this was not possible given time and
resource constraints.
Policy Implications and Recommendations
• Further study is needed to confirm some of the protec-
tive factors found in the CSHA and in other studies (coffee
drinking, vaccinations, use of estrogen therapy) before
policy recommendations can be made.
• The protective effect of regular physical activity for AD
provides an additional reason for the promotion of regu-
lar physical activity at all ages. Education and ongoing
mental activity are likely equally important.[51]
• Although the CSHA covers the years 1991 to 2001,
ongoing surveillance of the incidence and prevalence of
dementia is needed to monitor the impact of preventive
strategies and treatments as well as the aging of the popu-
lation. This is not feasible using the usual sources of data
(hospitalizations, mortality, physicians' visits) since in
only a fairly small fraction of dementia cases would
dementia be listed as a diagnosis.
Note
The views expressed in this report do not necessarily rep-
resent the views of the Canadian Population Health Initi-
ative, the Canadian Institute for Health Information or
Health Canada.
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